Funding boost means more medicines for more New Zealanders

24 June 2024 - PHARMAC welcomes the Government’s funding boost which will see about 175,000 more people receiving the medicines they ...

Read more →

Takeda receives approval from European Commission for Fruzaqla in previously treated metastatic colorectal cancer

21 June 2024 - Approval based on results from positive, global, Phase 3 FRESCO-2 trial. ...

Read more →

FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C mutated colorectal cancer

21 June 2024 - Today, the FDA granted accelerated approval to adagrasib (Krazati; Mirati Therapeutics) plus cetuximab for adults with ...

Read more →

European Medicines Agency validates Bristol Myers Squibb’s application for subcutaneous nivolumab

21 June 2024 - Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation ...

Read more →

Too much politics clouding cancer drugs process, decision - PHARMAC minister

20 June 2024 - There is a danger cancer patients are being overlooked in the political points-scoring that has arisen ...

Read more →

Truqap plus Faslodex approved in the EU for patients with advanced oestrogen receptor positive breast cancer

20 June 2024 - Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or ...

Read more →

Golidocitinib approved in China as first in class JAK1 only inhibitor for the treatment of relapsed or refractory peripheral T-cell lymphoma

19 June 2024 - Golidocitinib is a first-in-class Janus kinase 1 only inhibitor approved for the treatment of relapsed/refractory PTCL based ...

Read more →

National cancer drug promise: PHARMAC Minister won’t guarantee those 13 drugs will be funded

19 June 2024 - The minister responsible for New Zealand’s drugbuying agency PHARMAC is at odds with the Minister of ...

Read more →

PHARMAC improves access to breast cancer treatments

18 June 2024 - PHARMAC has changed the criteria for two breast cancer medicines which means people with a particular ...

Read more →

US FDA rare paediatric disease designation granted to RC220 bisantrene for the treatment of paediatric AML

18 June 2024 - Race Oncology is pleased to announce that the US FDA has extended rare paediatric disease designation ...

Read more →

Subcutaneous amivantamab biologics license application submitted to US FDA for patients with EGFR mutated non-small-cell lung cancer

17 June 2024 - Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five minute administration ...

Read more →

FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma

17 June 2024 - Today, the FDA approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for ...

Read more →

FDA approves blinatumomab as consolidation for CD19 positive Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemia

14 June 2024 - Today, the FDA approved blinatumomab (Blincyto, Amgen) for adult and paediatric patients one month and older ...

Read more →

FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer

14 June 2024 - Today, the FDA approved durvalumab (Imfinzi, AstraZeneca) with carboplatin plus paclitaxel followed by single-agent durvalumab for ...

Read more →

FDA grants accelerated approval to repotrectinib for adult and paediatric patients with NTRK gene fusion positive solid tumours

13 June 2024 - Today, the FDA granted accelerated approval to repotrectinib (Augtyro, BMS) for adult and paediatric patients 12 ...

Read more →